SAN DIEGO, Apr 13, 2012 (BUSINESS WIRE) —ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on innovative treatments that address unmet medical needs inneurological and related central nervous system disorders, todayannounced that it will present at the 19th Annual FutureLeaders in the Biotech Industry Conference on Friday, April 20, 2012, at11:00 a.m. Eastern Time at the Millennium Broadway Hotel in New YorkCity.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through May 4, 2012.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on innovative treatmentsthat address unmet medical needs in neurological and related centralnervous system disorders. ACADIA has four product candidates in clinicaldevelopment led by pimavanserin, which is in Phase III development as apotential first-in-class treatment for Parkinson's disease psychosis.ACADIA's other clinical-stage products include collaborative programsfor chronic pain and glaucoma with Allergan, Inc. and a collaborativeprogram for schizophrenia with Meiji Seika Pharma Co., Ltd. In addition,ACADIA has preclinical programs directed at Parkinson's disease andother neurological disorders. All of ACADIA's product candidates aresmall molecules that emanate from discoveries made using its proprietarydrug discovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA'sdrug discovery and development programs either alone or with a partner,including clinical trials, and the benefits to be derived from ACADIA'sproduct candidates, in each case including pimavanserin. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA's annual report on Form 10-K for the year ended December 31, 2011as well as other subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.
SOURCE: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, ExecutiveVice President,
Chief Financial Officer and Chief BusinessOfficer
(858) 558-2871